EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early Clinical Effects and Anti-Adhesive Activity of Phytoniring Drugs BNO1012/1016 And BNO1030 in a Critical "Window of Opportunity" for Prevention of Progression of Respiratory Infections

Vasyl Popovych, Ivanna Koshel

SSP Modern Pharmacy and Medicine · 2026

DOI: 10.53933/431kgk10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SSP Modern Pharmacy and Medicine, 2026. Verfasst von Vasyl Popovych und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory infections are one of the most common causes of seeking medical attention and unreasonable prescription of antibiotics. Their progression is largely determined by the events of the critical "window of opportunity" – the first 48-72 hours. During this period, the main links in the pathogenesis of inflammation, changes in the microbiome and increased adhesion of microorganisms to the epithelium create conditions for the formation of bacterial biofilms that underlie the progression of inflammation, relapses, and chronicity. Restriction of antibiotic therapy in viral processes and the need to reduce the unreasonable use of antibiotics, interest in phytonyring drugs is growing. These multicomponent herbal remedies have antiviral, anti-inflammatory, secretolytic and immunomodulatory properties, which makes them promising for influencing the early stages of the pathogenesis of respiratory infections, including potential modification of pathogen adhesion. The purpose of the study was to evaluate the early clinical effects and anti-adhesive effect of the phytonyring drugs Sinupret (BNO1012/1016) and Imupret (BNO1030) in acute respiratory infections in the context of their potential ability to prevent progression and recurrence. An analysis of literature data on the efficacy of BNO1012/1016 in acute viral and postviral rhinosinusitis and BNO1030 in acute nonbacterial tonsillitis and its recurrent forms was carried out. The effect of drugs on the adhesive activity of Streptococcus pyogenes, Staphylococcus Aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus group G and Candida was evaluated albicans. Clinical data demonstrate that phytoniring drugs BNO1012/1016 and BNO1030 provide a pronounced early (in the first 48-72 hours) therapeutic effect in respiratory infections. BNO1016 reduces the severity of typical symptoms of acute viral and postviral rhinosinusitis and significantly reduces the frequency of progression of the viral process into post-viral (-79.5%) and bacterial (-58.7%) rhinosinusitis. BNO1030 pFig. corrects the regression of symptoms of acute non-bacterial tonsillitis (therapeutic gain is 4 days) and reduces the recurrence rate by 66.6% within a year. The clinical data obtained are confirmed by experimental: BNO1016 significantly reduced the adhesive activity of most of the clinical strains studied, Streptococcus pyogenes, Staphylococcus aureus and Staphylococcus epidermidis. BNO1030 showed a pronounced anti-adhesive effect against Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus group G and Candida albicans. The ability of drugs to reduce the adhesion of pathogens – an early stage in the formation of biofilms – may be one of the key pathogenetic mechanisms of their clinical preventive efficacy. Sinupret (BNO1012/1016) provides an early clinical effect in acute viral and postviral rhinosinusitis and reduces the progression to post-viral and bacterial forms. Imupret (BNO1030) shows rapid improvement in the symptoms of acute non-bacterial tonsillitis and reduces the recurrence rate. Experimental data confirm these clinical effects: both drugs reduce the adhesion of clinically relevant pathogens, which is an early stage in the formation of biofilms. The combination of early clinical exposure and anti-adhesive activity forms the pathogenetic basis of the preventive action of BNO1012/1016 and BNO1030 on the progression and recurrence of respiratory infections.

Zitieren

APA

Popovych, V., & Koshel, I. (2026). Early Clinical Effects and Anti-Adhesive Activity of Phytoniring Drugs BNO1012/1016 And BNO1030 in a Critical "Window of Opportunity" for Prevention of Progression of Respiratory Infections. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/431kgk10

Vancouver

Popovych V, Koshel I. Early Clinical Effects and Anti-Adhesive Activity of Phytoniring Drugs BNO1012/1016 And BNO1030 in a Critical "Window of Opportunity" for Prevention of Progression of Respiratory Infections. SSP Modern Pharmacy and Medicine. 2026. doi:10.53933/431kgk10

BibTeX
@article{Popovych2026,
  author = {Popovych, Vasyl and Koshel, Ivanna},
  title = {Early Clinical Effects and Anti-Adhesive Activity of Phytoniring Drugs BNO1012/1016 And BNO1030 in a Critical "Window of Opportunity" for Prevention of Progression of Respiratory Infections},
  journal = {SSP Modern Pharmacy and Medicine},
  year = {2026},
  doi = {10.53933/431kgk10}
}
Kostenlos starten →